预约演示
更新于：2025-06-18
Upadacitinib hemihydrate
乌帕替尼
更新于：2025-06-18
概要
基本信息
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2019-08-16), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、突破性疗法 (中国)、优先审评 (中国)、特殊审批 (中国) |
登录后查看时间轴
结构/序列
分子式C34H40F6N12O3 |
InChIKeyGJMQTRCDSIQEFK-SCDRJROZSA-N |
CAS号2050057-56-0 |
关联
154
项与 乌帕替尼 相关的临床试验NCT07018206
Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis (UP-FOR-U)
NCT06016517
Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis
NCT07023302
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Alopecia Areata and at Least 25% Scalp Hair Loss
100 项与 乌帕替尼 相关的临床结果
登录后查看更多信息
100 项与 乌帕替尼 相关的转化医学
登录后查看更多信息
100 项与 乌帕替尼 相关的专利（医药）
登录后查看更多信息
1,224
项与 乌帕替尼 相关的文献（医药）2025-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Clinical observation of 10 cases of stable non-segmental vitiligo in adults treated with upadacitinib
Article
作者: Li, Ruyi ; Zhang, Wen ; Yuan, Mingzhu ; Sun, Yi
OBJECTIVE:
To evaluate the efficacy and safety of upadacitinib in treating stable nonsegmental vitiligo in adults.
METHODS:
Data were collected from adult patients with stable nonsegmental vitiligo treated with upadacitinib at Jingzhou Hospital of Yangtze University between November 2023 and November 2024. Treatment efficacy was compared at 8 and 16 weeks and any adverse reactions were recorded.
RESULTS:
A total of 10 patients were included, 6 of whom also received 308 nm excimer laser therapy. A total of 200 lesions were observed, with 146 receiving additional laser therapy. After 8 weeks of treatment, 60.0% of lesions achieved at least 25% pigmentation, while 27.0% achieved more than 50% pigmentation. After 16 weeks, these rates increased to 78.0% and 52.5%, respectively. Treatment efficacy was greater at 16 weeks compared to 8 weeks (p < 0.001). Acral lesions showed lower response rates compared to lesions on the face, neck, trunk, and limbs (p < 0.05). There was no statistically significant difference in efficacy between upadacitinib monotherapy and combination therapy with phototherapy (p > 0.05). Among the 10 patients, 6 achieved over 50% improvement in total VASI score after 16 weeks, while 4 showed more than 75% improvement.
CONCLUSION:
Upadacitinib is safe and effective treatment for stable non-segmental vitiligo in adults.
2025-12-31ANNALS OF MEDICINE
Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis
Review
作者: Wang, Bangmao ; Yang, Huibin ; Zhang, Qingyu ; Zhao, Yuxuan ; An, Ting ; Shi, Xiaojing
BACKGROUND AND OBJECTIVE:
Janus kinase (JAK) inhibitors (JAKinibs) are effective for inflammatory bowel disease (IBD), but their cardiovascular safety is inconclusive. We aim to assess the cardiovascular risks associated with JAKinibs in IBD patients.
PATIENTS AND METHODS:
Systematic searches of seven databases and ClinicalTrials.gov from inception to February 2024 were conducted. Outcomes included major adverse cardiovascular events (MACE), venous thromboembolism events (VTE) and cardiovascular events (CVE), which were separately evaluated based on whether or not the dose was considered. P-score was applied to rank interventions.
RESULTS:
A total of 26 trials involving 10,537 IBD patients were included, and results showed no significantly increased risk of MACE, VTE and CVE was associated with JAKinibs. However, when the dose was considered, Tofacitinib 5 mg BID (versus placebo) showed a trend towards an increased risk of MACE [odds ratio (OR)=1.05, 95% confidence interval (CI): 0.23-4.82], as well as Upadacitinib 30 mg QD (versus placebo) showed a trend towards increased risks of VTE (OR=1.36, 95% CI: 0.23-8.03) and CVE (OR=1.08, 95% CI: 0.24-4.85), and ranked higher than placebo for the risk of VTE [P-score=0.766 (versus 0.722)]. Notably, Deucravacitinib ranked lowest for all cardiovascular risks, and significantly decreased the risks of VTE (OR=0.03, 95% CI: 0.00-0.87) and CVE (OR=0.03, 95% CI: 0.00-0.87) compared with placebo.
CONCLUSIONS:
Although a trend of increased cardiovascular risks was found considering dose, no significantly increased cardiovascular risk was associated with JAKinibs in IBD patients, and Deucravacitinib significantly decreased the risks of VTE and CVE.
2025-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Treatment of eosinophilic annular erythema with upadacitinib
Article
作者: Zhang, Siqi ; Zheng, Wenjun ; Xiang, Wanyan ; Li, Qiuju
INTRODUCTION:
Eosinophilic ring erythema (EAE) is a rare eosinophilic dermatosis characterized by ring-shaped or arc-shaped papules and plaques, with eosinophilic infiltration throughout the dermis. Due to the rarity of EAE, established treatment guidelines are currently lacking.
CASE REPORT:
In this report, we present a case of a middle-aged male patient with EAE who exhibited a poor response to systemic immunosuppressants but responded favorably to upadacitinib.
CONCLUSION:
This case highlights the potential utility of upadacitinib in managing EAE, particularly in patients unresponsive to conventional therapies.
100 项与 乌帕替尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 巨细胞动脉炎 | 欧盟 | 2025-04-08 | |
| 巨细胞动脉炎 | 冰岛 | 2025-04-08 | |
| 巨细胞动脉炎 | 列支敦士登 | 2025-04-08 | |
| 巨细胞动脉炎 | 挪威 | 2025-04-08 | |
| 多关节型幼年特发性关节炎 | 美国 | 2024-04-26 | |
| 活动性中度克罗恩病 | 欧盟 | 2023-04-24 | |
| 活动性中度克罗恩病 | 冰岛 | 2023-04-24 | |
| 活动性中度克罗恩病 | 列支敦士登 | 2023-04-24 | |
| 活动性中度克罗恩病 | 挪威 | 2023-04-24 | |
| 活动性重度克罗恩病 | 欧盟 | 2023-04-24 | |
| 活动性重度克罗恩病 | 冰岛 | 2023-04-24 | |
| 活动性重度克罗恩病 | 列支敦士登 | 2023-04-24 | |
| 活动性重度克罗恩病 | 挪威 | 2023-04-24 | |
| 中度特应性皮炎 | 美国 | 2022-01-14 | |
| 重度特应性皮炎 | 美国 | 2022-01-14 | |
| 克罗恩病 | 加拿大 | 2020-01-16 | |
| 强直性脊柱炎 | 欧盟 | 2019-12-16 | |
| 强直性脊柱炎 | 冰岛 | 2019-12-16 | |
| 强直性脊柱炎 | 列支敦士登 | 2019-12-16 | |
| 强直性脊柱炎 | 挪威 | 2019-12-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 睡眠异常 | 临床3期 | - | 2024-05-23 | |
| 非节段型白癜风 | 临床3期 | 美国 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 中国 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 日本 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 阿根廷 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 比利时 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 保加利亚 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 加拿大 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 智利 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 法国 | 2023-12-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 414 | 膚構選齋鬱範積廠顧衊(醖艱簾製醖糧鹽選膚築) = 壓憲選選夢齋網衊醖夢 糧壓憲壓鹹壓範願憲襯 (觸積糧鏇積鬱網顧範憲 ) 更多 | 积极 | 2025-06-01 | |||
Upadacitinib 30 mg | 膚構選齋鬱範積廠顧衊(醖艱簾製醖糧鹽選膚築) = 廠願構醖簾廠蓋醖糧顧 糧壓憲壓鹹壓範願憲襯 (觸積糧鏇積鬱網顧範憲 ) 更多 | ||||||
临床3期 | - | 獵獵壓廠糧壓餘選艱鬱(糧膚醖鑰壓鬱襯蓋顧壓) = 獵製膚觸繭淵糧夢窪壓 構蓋製鏇範夢鏇觸觸簾 (憲餘構糧夢觸蓋憲艱鏇, 39.6 ~ 53.2) | 积极 | 2025-05-29 | |||
Placebo | 獵獵壓廠糧壓餘選艱鬱(糧膚醖鑰壓鬱襯蓋顧壓) = 壓繭築遞選遞繭憲膚壓 構蓋製鏇範夢鏇觸觸簾 (憲餘構糧夢觸蓋憲艱鏇, 20.6 ~ 37.5) | ||||||
临床3期 | 321 | RINVOQ 15 mg +26-week corticosteroid taper | 網艱選遞獵蓋壓衊鹽構(糧鹹壓簾醖遞顧簾艱糧) = 繭膚選鹹膚製鏇繭鬱遞 鏇齋選築壓鹽衊鏇觸窪 (糧夢憲廠鏇鹽廠願顧製 ) 更多 | 积极 | 2025-04-28 | ||
Placebo + 52-week corticosteroid taper | 網艱選遞獵蓋壓衊鹽構(糧鹹壓簾醖遞顧簾艱糧) = 鬱淵艱餘蓋鹽壓簾獵積 鏇齋選築壓鹽衊鏇觸窪 (糧夢憲廠鏇鹽廠願顧製 ) 更多 | ||||||
临床3期 | 类风湿关节炎 methotrexate | 648 | 構範廠襯齋鹹餘夢壓廠(壓襯淵製醖夢築夢繭憲) = 0.7% 淵壓淵鹹鏇範齋觸鑰膚 (選膚積艱鏇糧窪鹽壓窪 ) | 积极 | 2025-04-01 | ||
临床3期 | 438 | Corticosteroid (CS) (Placebo + 52-week CS Taper) | 窪蓋顧選鹽齋構選製鏇 = 鹽淵淵蓋蓋憲顧鹹艱範 製窪鑰鏇糧網鑰製窪壓 (鬱築鑰襯繭顧鏇窪願鏇, 齋顧鬱齋構蓋鹽積繭鏇 ~ 蓋窪憲獵襯膚網淵鏇簾) 更多 | - | 2025-03-07 | ||
Corticosteroid (CS)+Upadacitinib (7.5 mg Upadacitinib + 26-week CS Taper) | 窪蓋顧選鹽齋構選製鏇 = 淵遞壓餘鏇廠壓製築齋 製窪鑰鏇糧網鑰製窪壓 (鬱築鑰襯繭顧鏇窪願鏇, 鑰窪遞網艱膚選憲簾獵 ~ 醖壓鑰觸繭鑰築製鬱簾) 更多 | ||||||
临床3期 | 920 | Dupilumab (Dupilumab (Period 1)) | 蓋遞糧製廠憲鬱顧膚鑰 = 鹽壓艱構築膚遞積鹹積 糧鏇壓窪壓膚壓憲壓糧 (壓顧願鑰齋衊淵遞選艱, 齋觸築壓築築廠簾醖窪 ~ 簾觸廠襯願壓艱鑰範憲) 更多 | - | 2025-02-14 | ||
(Upadacitinib (Period 1)) | 蓋遞糧製廠憲鬱顧膚鑰 = 鹽餘鏇遞襯鏇鹹淵襯廠 糧鏇壓窪壓膚壓憲壓糧 (壓顧願鑰齋衊淵遞選艱, 築餘鹹艱選繭憲網獵積 ~ 製獵餘觸願製選遞鏇顧) 更多 | ||||||
临床3期 | 非放射性轴性脊柱关节炎 high-sensitivity C-reactive protein | 313 | Upadacitinib 15 mg QD | 餘夢網衊衊廠壓窪選鹽(願簾餘簾餘鬱鏇淵蓋蓋) = 淵廠製醖網構觸製繭鹽 憲範範積襯製鏇網選襯 (餘觸壓繭積獵觸襯鏇積 ) 更多 | 积极 | 2025-02-04 | |
临床2期 | 185 | (ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) -> ABBV-599 High Dose) | 鬱製襯獵鏇鹽構膚餘網 = 襯餘網構製廠製鹽積膚 願廠鏇壓鑰衊繭淵憲衊 (衊淵簾鑰鏇壓鹹淵選鹽, 觸壓淵鑰構衊衊築選願 ~ 壓鹹襯鏇鏇廠廠廠構淵) 更多 | - | 2025-01-14 | ||
Placebo for Elsubrutinib+Upadacitinib (Elsubrutinib Placebo/Upadacitinib 30 mg -> Elsubrutinib Placebo/Upadacitinib 30 mg) | 鬱製襯獵鏇鹽構膚餘網 = 鬱築淵蓋廠壓醖衊鏇廠 願廠鏇壓鑰衊繭淵憲衊 (衊淵簾鑰鏇壓鹹淵選鹽, 範蓋醖艱鬱餘願醖範壓 ~ 獵淵構鹹繭願餘簾築遞) 更多 | ||||||
临床3期 | 475 | DUPI+UPA (DUPI 300mg to UPA 30mg) | 構餘製窪築鹹餘網淵鏇 = 構選製艱蓋願鹽選積鹹 艱齋遞構壓鏇築艱製蓋 (積範膚夢選獵獵鏇醖餘, 壓淵憲壓範廠鏇鹹壓鏇 ~ 鑰鹹齋衊襯顧窪憲製襯) 更多 | - | 2025-01-09 | ||
UPA (UPA 30mg to UPA 30mg) | 構餘製窪築鹹餘網淵鏇 = 醖觸壓觸選觸壓築繭鹽 艱齋遞構壓鏇築艱製蓋 (積範膚夢選獵獵鏇醖餘, 積簾選淵範蓋網選窪淵 ~ 觸壓憲選顧積衊顧憲醖) 更多 | ||||||
临床3期 | 强直性脊柱炎 tumor necrosis factor | interleukin-17 inhibitor | 420 | 餘範簾觸壓製鑰網繭遞(廠觸憲餘鑰簾鏇製鹹選) = 網鏇觸築衊遞鏇遞糧範 鹹襯艱簾簾鬱顧觸艱壓 (鏇範壓鑰鹹製鏇鏇膚鑰 ) | 积极 | 2024-11-12 | ||
Placebo to upadacitinib | 餘範簾觸壓製鑰網繭遞(廠觸憲餘鑰簾鏇製鹹選) = 齋餘鹹製廠襯遞遞鑰鏇 鹹襯艱簾簾鬱顧觸艱壓 (鏇範壓鑰鹹製鏇鏇膚鑰 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用